We discovered that COMP, which is normally highly restricted, is expressed in breast cancer, prostate cancer, periampullary adenocarcinoma, and colorectal cancer [1–4], while other groups reported its expression in colon, thyroid, and urothelial carcinoma [5–7]. Here, COMP is linked to prostate carcinoma.